Journal
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 19, Issue 6, Pages 326-331Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2019.03.004
Keywords
Allogenic stem cell transplantation; CCR4 mutaion; Conventional chemotherapy; Mogamulizumab; T-cell repertoire
Categories
Ask authors/readers for more resources
Mogamulizumab, a defucosylated humanized monoclonal antibody against the C-C chemokine receptor 4 (CCR4), has been approved for the treatment of relapsed adult T-cell leukemia/lymphoma (ATL). Compared with conventional chemotherapy, mogamulizumab monotherapy displayed more efficacy in relapsed ATL, making mogamulizumab a promising therapeutic agent. However, mogamulizumab could increase graft-versus-host disease, resulting in poor survival outcome in the allogenic stem cell transplant (allo-SCT) setting. It is possible that the efficacy of mogamulizumab could be established by the occurrence of skin rashes and/or CCR4 mutational status. Hence, this study reviews the current treatment strategies for patients with ATL and focuses on the safety and efficacy (single-agent and combined with chemotherapy or allo-SCT) of mogamulizumab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available